Sumitomo Dainippon, Roivant to create £2.4bn biopharma alliance
Under the deal, Sumitomo Dainippon Pharma will have the option to acquire up to six more Vants of Roivant. Additionally, the Japanese firm will take an equity stake
Under the deal, Sumitomo Dainippon Pharma will have the option to acquire up to six more Vants of Roivant. Additionally, the Japanese firm will take an equity stake
Under the terms of the agreement, X-Chem will utilize its DEX screening platform, which takes advantage of advanced DEX library designs and proprietary informatics tools, to search for
Endo’s operating company Par Pharmaceutical, Inc. expects to distribute the product through specialty pharmacies beginning this month. Nitisinone capsules are indicated for the treatment of adult and pediatric
The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound
STOP-301 is evaluating the safety of long-term, intermittent use of INP104 for 24-week and 52-week data points and will also collect efficacy data of INP104 as assessed by
A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm
The Maryland-based Insilico Medicine claimed that GENTRL can fast track the drug discovery process from years to days. The company is said to have validated the AI technology
Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type
Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also
The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral